Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Stockwatch: The Biotech Upgrade Cycle

This article was originally published in Scrip

Executive Summary

One of the positive investment attributes of the technology sector is the upgrade cycle. The continual advancements that result in faster speed, longer battery life and more features translate into consumer demand that justifies discarding last year's phone in favour of this year's model. With so many biotech companies coming to the market in the current IPO window, many are developing drugs that are upgrades of those already on the market.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029811

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel